ADVFN ADVFN

Hot Features

Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
Kyowa Hakko Kogyo (PK)

Kyowa Hakko Kogyo (PK) (KYKOF)

14,425
0,00
(0,00%)
Fermé 07 Juin 10:00PM

Kyowa Hakko Kogyo (PK) (KYKOF) Action

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Statistiques et détails clés

Dernier
14,425
( - )
Prix Achat
12,73
Prix Vente
15,36
Volume échangé
-
0,00 Fourchette du Jour 0,00
12,42 Plage de 52 semaines 18,00
Cap du marché
Clôture Veille
14,425
Ouverture
-
Dernière Transaction
Dernière heure de transaction
Volume financier
-
VWAP
-
Volume moyen (3 m)
US$ 1 596 232
Actions en circulation
523 486 836
Rendement du Dividende (LTM)
62 (2,94%)
Ratio Cours sur Bénéfices
17,99
Bénéfice par action (BPA)
139,27
Chiffre d'affairess (LTM)
510,57B
Bénéfice net (LTM)
72,91B

À propos de Kyowa Hakko Kogyo (PK)

Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, and marketing of pharmaceuticals in Japan, the Americas, Europe, Asia, and internationally. The company offers Ziftomenib, an oral menin inhibitor for the treatment of adult relapsed or refractory and acute myeloid leukemia w... Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, and marketing of pharmaceuticals in Japan, the Americas, Europe, Asia, and internationally. The company offers Ziftomenib, an oral menin inhibitor for the treatment of adult relapsed or refractory and acute myeloid leukemia with a nucelophosmin1 mutation; and Lumicef for the treatment of palmoplantar pustulosis. It also develops KHK4083/AMG 451 rocatinlimab, which is in Phase III clinical trial for the treatment of moderate to severe atopic dermatitis and prurigo nodularis; KK8398 infigratinib, which is in Phase III clinical trial for the treatment of achondroplasia; OTL-203, which is in Phase III clinical trial for the treatment of hurler syndrome; KHK4951 tivozanib, which is in Phase II clinical trial for the treatment of diabetic macular edema and neovascular age-related macular degeneration; and OTL-201, which is in Phase II clinical trial for the treatment of sanfilippo syndrome type A. In addition, the company is involved in the development of KK2260 and KK2269, which are both in Phase I clinical trials for the treatment of advanced or metastatic solid tumors; KK2845, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; KK3910, which is in Phase I clinical trial for the treatment of essential hypertension; KK4277, which is in Phase I clinical trial for the treatment of systemic/cutaneous lupus erythematosus; and KK8123, which is in Phase I clinical trial for the treatment of X-linked hypophosphatemia. It has a partnership with La Jolla Institute for Immunology for research in disease areas; AstraZeneca for severe asthma treatment; and AMGEN for therapeutic drugs development. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in July 2019. Kyowa Kirin Co., Ltd. was incorporated in 1949 and is headquartered in Chiyoda, Japan. The company operates as a subsidiary of Kirin Holdings Company, Limited. Show more

Secteur
Healthcare
Industrie
Pharmaceuticals
Siège social
Chiyoda, Japan
Fondé
2026
Kyowa Hakko Kogyo (PK) est coté dans le secteur Healthcare de la OTC Markets avec le ticker KYKOF. Le dernier cours de clôture d'Kyowa Hakko Kogyo (PK) était de US$14,43. Au cours de la dernière année, les actions de Kyowa Hakko Kogyo (PK) ont été négociées dans une fourchette de prix de US$ 12,42 à US$ 18,00.

Kyowa Hakko Kogyo (PK) compte actuellement 523 486 836 actions en circulation. La capitalisation boursière d'Kyowa Hakko Kogyo (PK) est de US$7,55 milliard. Kyowa Hakko Kogyo (PK) a un ratio cours/bénéfice (ratio PE) de 17.99.

KYKOF Dernières nouvelles

Aucune actualité à afficher pour le moment.
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10000000CS
40014.42515.07422214.4251855814.45648506CS
12-0.625-4.1528239202715.0515.07422214.425633614.47053608CS
26-2.165-13.050030138616.591812.42289014.84450682CS
52-2.715-15.840140023317.141812.42194415.25766054CS
156-5.138-26.263865460319.56322.21412.316202316.81838922CS
260-18.3745-56.020671046832.799537.33212.316222120.83534881CS

KYKOF - Frequently Asked Questions (FAQ)

What is the current Kyowa Hakko Kogyo (PK) share price?
The current share price of Kyowa Hakko Kogyo (PK) is US$ 14,425
How many Kyowa Hakko Kogyo (PK) shares are in issue?
Kyowa Hakko Kogyo (PK) has 523 486 836 shares in issue
What is the market cap of Kyowa Hakko Kogyo (PK)?
The market capitalisation of Kyowa Hakko Kogyo (PK) is USD 7,55B
What is the 1 year trading range for Kyowa Hakko Kogyo (PK) share price?
Kyowa Hakko Kogyo (PK) has traded in the range of US$ 12,42 to US$ 18,00 during the past year
What is the PE ratio of Kyowa Hakko Kogyo (PK)?
The price to earnings ratio of Kyowa Hakko Kogyo (PK) is 17,99
What is the cash to sales ratio of Kyowa Hakko Kogyo (PK)?
The cash to sales ratio of Kyowa Hakko Kogyo (PK) is 2,57
What is the registered address of Kyowa Hakko Kogyo (PK)?
The registered address for Kyowa Hakko Kogyo (PK) is Otemachi Financial City Grand Cube, Chiyoda, Tokyo, 100-0004
What is the Kyowa Hakko Kogyo (PK) website address?
The website address for Kyowa Hakko Kogyo (PK) is www.kyowakirin.com
Which industry sector does Kyowa Hakko Kogyo (PK) operate in?
Kyowa Hakko Kogyo (PK) operates in the Pharmaceuticals sector

KYKOF Transactions

Plus

Transactions différées

Pour obtenir des transactions en temps réel, améliorez votre compte

Passer à la version en temps réel
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

Delayed Upgrade Clock